Standout Papers
- Targeting FLT3 mutations in AML: review of current knowledge and evidence (2019)
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia (2012)
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) (2009)
- Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia (2022)
- The clinical impact of the molecular landscape of acute myeloid leukemia (2023)
Immediate Impact
41 by Nobel laureates 26 from Science/Nature 62 standout
Citing Papers
Acute myeloid leukaemia
2023 Standout
Designed protein logic to target cells with precise combinations of surface antigens
2020 StandoutScienceNobel
Works of Mark J. Levis being referenced
S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML
2022
Inhibitory Anti-FLT3 Antibodies Are Capable of Mediating Antibody-Dependent Cell-Mediated Cytotoxicity and Reducing Engraftment of Acute Myelogenous Leukemia Blasts in Nonobese Diabetic/Severe Combined Immunodeficient Mice
2005
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Mark J. Levis | 11070 | 4187 | 6709 | 315 | 14.1k | |
| Michael Lübbert | 7074 | 2162 | 7287 | 293 | 12.4k | |
| Carlo Gambacorti‐Passerini | 7750 | 5384 | 4913 | 342 | 13.4k | |
| Claude Preudhomme | 9158 | 4296 | 5641 | 351 | 13.0k | |
| Claudia Schoch | 8724 | 3342 | 5064 | 194 | 11.2k | |
| Richard F. Schlenk | 9731 | 3588 | 6268 | 242 | 13.1k | |
| Tessa L. Holyoake | 7343 | 4623 | 3745 | 216 | 10.9k | |
| Christine Chomienne | 6721 | 1922 | 9934 | 246 | 12.6k | |
| Azra Raza | 8686 | 3501 | 5409 | 273 | 12.1k | |
| Hitoshi Kiyoi | 5264 | 1965 | 4333 | 275 | 8.8k | |
| David Grimwade | 12222 | 2882 | 8014 | 145 | 14.9k |
All Works
Login with ORCID to disown or claim papers
Loading papers...